Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$1.2 million.

  • Phathom Pharmaceuticals' Gains from Investment Securities rose 1.79% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year increase of 51.09%. This contributed to the annual value of $6.2 million for FY2024, which is 35.37% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Gains from Investment Securities stood at -$1.2 million for Q3 2025, which was up 8.48% from -$1.3 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Gains from Investment Securities registered a high of $7.0 million during Q1 2025, and its lowest value of -$5.3 million during Q4 2023.
  • Moreover, its 3-year median value for Gains from Investment Securities was -$1.2 million (2025), whereas its average is $447,049.
  • Within the past 5 years, the most significant YoY rise in Phathom Pharmaceuticals' Gains from Investment Securities was 1,913.78% (2023), while the steepest drop was 2,546.27% (2023).
  • Over the past 4 years, Phathom Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at -$201,000 in 2022, then tumbled by 2,546.27% to -$5.3 million in 2023, then spiked by 83.15% to -$896,000 in 2024, then climbed by 1.79% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, -$1.3 million for Q2 2025, and $7.0 million during Q1 2025.